Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 15,100,000 shares, an increase of 7.2% from the August 31st total of 14,080,000 shares. Currently, 25.5% of the shares of the stock are sold short. Based on an average daily volume of 980,300 shares, the short-interest ratio is currently 15.4 days.
Day One Biopharmaceuticals Price Performance
Day One Biopharmaceuticals stock opened at $14.16 on Monday. Day One Biopharmaceuticals has a 1-year low of $9.67 and a 1-year high of $18.07. The stock’s 50 day moving average price is $14.14 and its 200 day moving average price is $14.48. The company has a market cap of $1.24 billion, a PE ratio of -5.64 and a beta of -1.51.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $0.90 million. On average, equities research analysts anticipate that Day One Biopharmaceuticals will post -1.68 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on DAWN
Insider Buying and Selling
In related news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the sale, the insider now owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares in the company, valued at approximately $15,785,490. The disclosure for this sale can be found here. Insiders sold a total of 68,748 shares of company stock worth $1,009,272 in the last 90 days. Insiders own 8.40% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in DAWN. Quintet Private Bank Europe S.A. raised its holdings in shares of Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the period. SG Americas Securities LLC purchased a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at $113,000. Point72 DIFC Ltd acquired a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at $124,000. Hsbc Holdings PLC purchased a new stake in Day One Biopharmaceuticals during the 2nd quarter worth $163,000. Finally, Bayesian Capital Management LP acquired a new position in shares of Day One Biopharmaceuticals during the first quarter worth about $221,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Articles
- Five stocks we like better than Day One Biopharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- Salesforce Stock Gets a Wall Street Boost, Cloud Businesses Back?
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Multi-Bagger Stocks to Buy Now for Explosive Growth
- Top Biotech Stocks: Exploring Innovation Opportunities
- Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.